Omega Diagnostics Group PLC
LSE:ODX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (0.3), the stock would be worth GBX-0.44 (120% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -1.4 | GBX2.2 |
0%
|
| Industry Average | 0.3 | GBX-0.44 |
-120%
|
| Country Average | 0.2 | GBX-0.32 |
-115%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Omega Diagnostics Group PLC
LSE:ODX
|
5.2m GBP | -1.4 | -1.4 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.4T JPY | 48.7 | 37.6 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.8B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
28.4B CHF | 26.3 | 36.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
88.8B DKK | 18 | 22.8 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.8B USD | 26 | 31.1 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.8B USD | -25.4 | -16 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.1B GBP | 12.6 | 31.1 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
37.9B CNY | 33.7 | 23 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
37.3B CNY | 10.3 | 21.9 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.1T KRW | -115.1 | -36.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.1 |
| Median | 0.2 |
| 70th Percentile | 0.4 |
| Max | 901.8 |
Other Multiples
Omega Diagnostics Group PLC
Glance View
Omega Diagnostics Group Plc is a holding company, which engages in the manufacture, development, and distribution of medical diagnostics products. The company is headquartered in Alva, Stirlingshire and currently employs 171 full-time employees. The company went IPO on 2004-03-18. The principal activities of the Company and its subsidiaries are the manufacture, development and distribution of medical diagnostics products. The firm operates through two segments: Health and Nutrition and Global Health. The Health and Nutrition segment specializes in the research, development and production of kits to aid the detection of immune reactions to food. The company also provides clinical analysis to the general public, clinics and health professionals as well as supplying the consumer Food Detective test. The Global Health segment specializes in the research, development, production and marketing of kits to aid the diagnosis of infectious diseases, including COVID-19. The firm's products include FoodPrint, Food Detective, CNS lab, VISITECT CD4 Advanced Disease, VISITECT COVID-19 IgM/IgA/IgG and VISITECT COVID-19 Antigen.
